China halted its markets for the second time this week as steep stock losses mounted. Domestic markets reacted with the Dow plummeting 230 points to 16,676. Nasdaq plunged 95 points to 4,740.
On the upside
Inventergy (Nasdaq: INVT) amended a patent purchase agreement with one of its patent partners that will save the company approximately $17.3 million in liabilities.
Dynavax Technologies (Nasdaq: DVAX) reported positive results from a Phase 3 clinical trial of its hepatitis B vaccine HEPLISAV-B(TM).
Shares of Barrick Gold (NYSE: ABX) and Harmony Gold (NYSE: HMY) continued rising as gold prices advanced again.
On the downside
SunEdison (NYSE: SUNE) priced $725 million in Second Lien Secured Term Loans and entered into exchange agreements with convertible senior note holders and perpetual convertible preferred stock owners.
Galena Biopharma (Nasdaq: GALE) priced its public offering of common stock and warrants at the discounted price of $1.10 per unit.
Epizyme (Nasdaq: EPZM) priced its public offering of approximately 13.33 million common shares at the discounted price of $9.00 per share.
In the broad market, declining issues outpaced advancers by a margin of more than 7 to 1 on the NYSE and by more than 6 to 1 on Nasdaq. The broader S&P 500 plunged 27 points to 1,962. Bitcoin climbed $19 to $450.
